Early phase II study of the new aromatase inhibitor YM511 in postmenopausal patients with breast cancer. Difficulty in clinical dose recommendation based on preclinical and phase I findings

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3533-3542

  Tominaga, Takeshi ^a,c   Suzuki, Takaichiro ^b  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c ASTELLAS PHARMA INC   (Japan)

Author keywords

Aromatase inhibitor; Breast cancer; Phase II study

Indexed keywords

4 [N (4 BROMOBENZYL) N (1,2,4 TRIAZOL 4 YL)AMINO]BENZONITRILE; AROMATASE INHIBITOR; CHOLESTEROL; ESTRADIOL;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CARCINOMA; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG INDICATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ESTRADIOL BLOOD LEVEL; FEMALE; GASTROINTESTINAL DISEASE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ESTRADIOL; ESTRONE; FEMALE; HUMANS; POSTMENOPAUSE; TRIAZOLES;

EID: 0043030057     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rose C and Mouridson H: Endocrine therapy of advanced breast cancer. Acta Oncol 27: 721-728, 1988.
2. Santen RJ, Manni A, Haevery H et al: Endocrine treatment of breast cancer in women. Endocr Rev 11(2): 221-265, 1990.
3. Buzdar AU, Jonat W, Howell A et al: Anastrozole versus megesterol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials, Arimidex Study Group. Cancer 83(6): 1146-11652, 1998.
4. Bonneetrre B, Thürlimann J, Robertson JFR et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 18(22): 3748-3757, 2000.
5. Nabholtz JM, Buzdar A, Pollak M et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women; results of a North American multicenter randomized trial. J Clin Oncol 18(22): 3758-3767, 2000.
6. Okada M, Yoden T, Kawaminami E et al: Studies on aromatase inhibitors. 1, Synthesis and biological evaluation of 4-amino-4H-1,2,4-triazole derivatives. Chem Pharm Bull Tokyo 44(10): 1871-1879, 1996.
7. Okada M, Yoden T, Kawaminami E et al: Studies on aromatase inhibitors. 2, Synthesis and biological evaluation of 1-amino-1H-1,2,4- triazole derivatives. Chem Pharm Bull Tokyo 45(2): 333-337, 1997.
8. Okada M, Yoden T, Kawaminami E et al: Studies on aromatase inhibitors. 2, Synthesis and biological evaluation of [(4-bromobenzyl)(4-cyanophenyl)amino]azoles and their azine analogues. Chem Pharm Bull Tokyo 45(3): 482-486, 1997.
9. Kudoh M, Susaki Y, Ideyama Y et al: The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511. J Steroid Biochem Mol Biol 54(5-6): 265-271, 1995.
10. Kudoh M, Susaki Y, Ideyama Y et al: Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell. J Steroid Biochem Mol Biol 58(2): 189-194, 1996.
11. Minaguchi H: Phase I study of YM511, a new aromatase inhibitor, in postmenopausal healthy women in Japan. 4th International Aromatase Conference: p.23, A-6,1996
12. Kudo et al: A study of a new non-steroidal aromatase inhibitor YM511 (Report III) uterus and DMBA induced breast cancer. Proc Japan Endocrine Society 66: 289, 1993.
13. Iveson TJ, Smith IE, Ahern J et al: Phase I study of the oral non-steroidal aromatase inhibitor CGS20267 in postmenopausal patients with advanced breast cancer. Cancer Res 53(2): 266-270, 1993.
14. Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer (1992).
15. Furue H, Hara Y, Imai Y et al: Criteria for evaluation of effect reinforcement of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28(1): 119-130, 1993.
16. Dormbernowsky P, Smith I, Falkson G et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16(2): 453-461, 1998.
17. Jonat W, Howell A, Blomqvist C et al: A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A(3): 404-412, 1996.
18. Tominaga T, Morimoto T, Ohashi Y et al: A pivotal double blind trial in Japan of an aromatase inhibitor Letrozole (third generation) vs. its predecessor fadrozole hydrochloride (second generation). Japan Letrozole Study Group. 25th Er S Med Onc C 11 Suppl 4: p.25, 2000.
19. CGS16949A study group: Phase II study (dose-finding study) of new aromatase inhibitor, CGS16949A. Gann to Kagakuryoho 21(4): 465-475, 1994.
20. Szymczak J, Milewocz A, Thijssen JHH et al: Concentration of sex steroids in adipose tissue after menopause. Steroids 63: 319-321, 1998.
21. Suzuki N, Yano T, Nakazawa N et al: A possible role of estrone produced in adipose tissues in modulating postmenopausal bone density. Maturitas 22: 9-12, 1995.
22. Henning M, Mikhail Gershanovich et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for poostmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group 19: 2596-2606, 2001.